Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX® in Portugal

Calcified Tissue International

Volumn 99, Issue 2, 2016, Pages 131-141

  Marques, Andréa ^a,b   Lourenço, Óscar ^c   Ortsäter, Gustaf ^d   Borgström, Fredrik ^d   Kanis, John A ^e   da Silva, José António P ^a,f  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b ESCOLA SUPERIOR DE ENFERMAGEM DE COIMBRA   (Portugal)

^c INESC COIMBRA   (Portugal)

^d Quantify Research   (Sweden)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

^f UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

10 year fracture probability; Cost effectiveness; FRAX; Intervention thresholds; Osteoporosis

Indexed keywords

ALENDRONIC ACID; DENOSUMAB; PARATHYROID HORMONE[1-34]; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; RISEDRONIC ACID;

ADULT; ALGORITHM; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FEMALE; FRAGILITY FRACTURE; HEALTH CARE COST; HIDDEN MARKOV MODEL; HIP FRACTURE; HUMAN; INCIDENCE; MALE; MIDDLE AGED; MORTALITY; OSTEOPOROSIS; PORTUGAL; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; AGED; COHORT ANALYSIS; COST BENEFIT ANALYSIS; ECONOMICS; POSTMENOPAUSE OSTEOPOROSIS; PROCEDURES;

AGED; ALENDRONATE; ALGORITHMS; BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; COST-BENEFIT ANALYSIS; DENOSUMAB; FEMALE; HIP FRACTURES; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; RISEDRONATE SODIUM;

EID: 84961575249     PISSN: 0171967X     EISSN: 14320827     Source Type: Journal    
DOI: 10.1007/s00223-016-0132-8     Document Type: Article

References (46)

1. Kanis JA, Oden A, McCloskey EV, Johansson H, Wahl DA, Cooper C (2012) A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int 23(9):2239–2256. doi:10.1007/s00198-012-1964-3
2. Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. Arch Osteoporos 8(1–2):136. doi:10.1007/s11657-013-0136-1
3. Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J, Burckhardt P, Cooper C, Christiansen C, Cummings S, Eisman JA, Fujiwara S, Gluer C, Goltzman D, Hans D, Krieg MA, La Croix A, McCloskey E, Mellstrom D, Melton Iii LJ, Pols H, Reeve J, Sanders K, Schott AM, Silman A, Torgerson D, Van Staa T, Watts NB, Yoshimura N (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18(8):1033–1046
4. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19(4):385–397. doi:10.1007/s00198-007-0543-5
5. Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, Cauley JA, Compston JE, Dawson-Hughes B, El-Hajj Fuleihan G, Johansson H, Leslie WD, Lewiecki EM, Luckey M, Oden A, Papapoulos SE, Poiana C, Rizzoli R, Wahl DA, McCloskey EV (2011) Interpretation and use of FRAX in clinical practice. Osteoporos Int 22(9):2395–2411. doi:10.1007/s00198-011-1713-z
6. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24(1):23–57. doi:10.1007/s00198-012-2074-y
7. Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A (2008) Case finding for the management of osteoporosis with FRAX—assessment and intervention thresholds for the UK. Osteoporos Int 19(10):1395–1408. doi:10.1007/s00198-008-0712-1
8. Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19(4):437–447. doi:10.1007/s00198-007-0550-6
9. Lippuner K, Johansson H, Borgstrom F, Kanis JA, Rizzoli R (2012) Cost-effective intervention thresholds against osteoporotic fractures based on FRAX(R) in Switzerland. Osteoporos Int 23(11):2579–2589. doi:10.1007/s00198-011-1869-6
10. Makras P, Athanasakis K, Boubouchairopoulou N, Rizou S, Anastasilakis AD, Kyriopoulos J, Lyritis GP (2015) Cost-effective osteoporosis treatment thresholds in Greece. Osteoporos Int 26(7):1949–1957. doi:10.1007/s00198-015-3055-8
11. Marques A, Mota A, Canhao H, Romeu JC, Machado P, Ruano A, Barbosa AP, Dias AA, Silva D, Araujo D, Simoes E, Aguas F, Rosendo I, Silva I, Crespo J, Alves JD, Costa L, Mascarenhas M, Lourenco O, Ferreira PL, Lucas R, Roque R, Branco JC, Tavares V, Johansson H, Kanis J, Pereira da Silva JA (2013) A FRAX model for the estimation of osteoporotic fracture probability in Portugal. Acta Reumatol Port 38(2):104–112
12. Ferreira LN, Ferreira PL, Pereira LN, Oppe M (2013) EQ-5D Portuguese population norms. Qual Life Res 23(2):425–430. doi:10.1007/s11136-013-0488-4
13. Marques A, Lourenco O, da Silva JA (2015) The burden of osteoporotic hip fractures in Portugal: costs, health related quality of life and mortality. Osteoporos Int. doi:10.1007/s00198-015-3171-5
14. Borgstrom F, Strom O, Kleman M, McCloskey E, Johansson H, Oden A, Kanis JA (2011) Cost-effectiveness of bazedoxifene incorporating the FRAX(R) algorithm in a European perspective. Osteoporos Int 22(3):955–965. doi:10.1007/s00198-010-1291-5
15. Jonsson B, Strom O, Eisman JA, Papaioannou A, Siris ES, Tosteson A, Kanis JA (2011) Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 22(3):967–982. doi:10.1007/s00198-010-1424-x
16. Strom O, Jonsson B, Kanis JA (2013) Intervention thresholds for denosumab in the UK using a FRAX(R)-based cost-effectiveness analysis. Osteoporos Int 24(4):1491–1502. doi:10.1007/s00198-012-2115-6
17. Jones ML, Wilkinson A (2006) Adverse effects and persistence with therapy in patients taking oral alendronate, etidronate or risedronate: systematic reviews (NICE). The University of Sheffield, School of Health and Related Research. http://www.nice.org.uk/guidance/index.jsp?action=download&o=36718. Accessed 5 Jan 2015
18. de Pina MF, Alves SM, Barbosa M, Barros H (2008) Hip fractures cluster in space: an epidemiological analysis in Portugal. Osteoporos Int 19(12):1797–1804. doi:10.1007/s00198-008-0623-1
19. Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, De Laet C, Jonsson B (2000) Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 11(8):669–674
20. Borgstrom F, Strom O, Coelho J, Johansson H, Oden A, McCloskey EV, Kanis JA (2010) The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int 21(3):495–505. doi:10.1007/s00198-009-0989-8
21. Oden A, Dawson A, Dere W, Johnell O, Jonsson B, Kanis JA (1998) Lifetime risk of hip fractures is underestimated. Osteoporos Int 8(6):599–603. doi:10.1007/s001980050105
22. Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, De Laet C, Jonsson B (2004) Mortality after osteoporotic fractures. Osteopor Int 15(1):38–42. doi:10.1007/s00198-003-1490-4
23. Kim K, Svedbom A, Luo X, Sutradhar S, Kanis JA (2014) Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm. Osteoporos Int 25(1):325–337. doi:10.1007/s00198-013-2521-4
24. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344(19):1434–1441. doi:10.1056/nejm200105103441904
25. Kanis JA, Adams J, Borgstrom F, Cooper C, Jonsson B, Preedy D, Selby P, Compston J (2008) The cost-effectiveness of alendronate in the management of osteoporosis. Bone 42(1):4–15. doi:10.1016/j.bone.2007.10.019
26. Freemantle N, Satram-Hoang S, Tang ET, Kaur P, Macarios D, Siddhanti S, Borenstein J, Kendler DL (2012) Final results of the DAPS (denosumab adherence preference satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 23(1):317–326. doi:10.1007/s00198-011-1780-1
27. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18):1809–1822. doi:10.1056/NEJMoa067312
28. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765. doi:10.1056/NEJMoa0809493
29. Borgstrom F, Johnell O, Kanis JA, Jonsson B, Rehnberg C (2006) At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int 17(10):1459–1471. doi:10.1007/s00198-006-0107-0
30. Kanis JA, Johnell O, Oden A, Borgstrom F, Zethraeus N, De Laet C, Jonsson B (2004) The risk and burden of vertebral fractures in Sweden. Osteoporos Int 15(1):20–26. doi:10.1007/s00198-003-1463-7
31. Royston P, Altman DG (1997) Approximating statistical functions by using fractional polynomial regression. J Roy Stat Soc 46(3):411–422
32. Sauerbrei W, Meier-Hirmer C, Benner A, Royston P (2006) Multivariable regression model building by using fractional polynomials: description of SAS, STATA and R programs. Comput Stat Data Anal 50(12):3464–3485
33. McCabe C, Claxton K, Culyer AJ (2008) The NICE cost-effectiveness threshold. Pharmacoeconomics 26(9):733–744
34. Kanis J (2008) Assessment of osteoporosis at the primary healthcare level. Technical Report, p61, WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield
35. European Commission Economic and Financial Affairs. http://ec.europa.eu/economy_finance/ameco/user/serie/ResultSerie.cfm. Accessed 7 Feb 2015
36. Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, Devlin N, Smith PC, Sculpher M (2015) Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess 19(14):1–503v–vi. doi:10.3310/hta19140
37. Nayak S, Roberts MS, Greenspan SL (2011) Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women. Ann Intern Med 155(11):751–761. doi:10.7326/0003-4819-155-11-201112060-00007
38. Nshimyumukiza L, Durand A, Gagnon M, Douville X, Morin S, Lindsay C, Duplantie J, Gagne C, Jean S, Giguere Y, Dodin S, Rousseau F, Reinharz D (2013) An economic evaluation: simulation of the cost-effectiveness and cost-utility of universal prevention strategies against osteoporosis-related fractures. J Bone Miner Res 28(2):383–394. doi:10.1002/jbmr.1758
39. Si L, Winzenberg TM, Palmer AJ (2014) A systematic review of models used in cost-effectiveness analyses of preventing osteoporotic fractures. Osteoporos Int 25(1):51–60. doi:10.1007/s00198-013-2551-y
40. Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, Oden A, Zethraeus N, Pfleger B, Khaltaev N (2005) Assessment of fracture risk. Osteoporos Int 16(6):581–589. doi:10.1007/s00198-004-1780-5
41. Briot K, Cortet B, Thomas T, Audran M, Blain H, Breuil V, Chapuis L, Chapurlat R, Fardellone P, Feron JM, Gauvain JB, Guggenbuhl P, Kolta S, Lespessailles E, Letombe B, Marcelli C, Orcel P, Seret P, Tremollieres F, Roux C (2012) 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. Joint Bone Spine 79(3):304–313. doi:10.1016/j.jbspin.2012.02.014
42. Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R (2014) Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 25(10):2359–2381. doi:10.1007/s00198-014-2794-2
43. Colombo GL, Montecucco CM (2013) Generic vs brand originator alendronate: analysis of persistence and compliance in five Local Healthcare Units in the Lombardy Region of Italy. Clin Cases Miner Bone Metab 10(3):195–198
44. Ringe JD, Moller G (2009) Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatol Int 30(2):213–221. doi:10.1007/s00296-009-0940-5
45. Hiligsmann M, Rabenda V, Gathon HJ, Ethgen O, Reginster JY (2010) Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int 86(3):202–210
46. Siggeirsdottir K, Aspelund T, Johansson H, Gudmundsson EF, Mogensen B, Jonsson BY, Gudnason V, McCloskey E, Oden A, Sigurdsson G, Kanis JA (2014) The incidence of a first major osteoporotic fracture in Iceland and implications for FRAX. Osteoporos Int 25(10):2445–2451. doi:10.1007/s00198-014-2777-3